妊娠期第一代与第二代抗精神病药使用与妊娠及出生结局风险
基于丹麦2004-2022年全国活产单胎队列,纳入7417例孕前使用抗精神病药孕妇,比较继续使用第一代(FG)或第二代(SG)与停药者的妊娠并发症及不良出生结局。FG不增加母体风险但NICU入住率升高;SG与母体代谢风险增加及早产风险降低相关。
要点
- FG继续使用不增加妊娠糖尿病和高血压风险,但NICU入住率较高。
- SG继续使用与妊娠糖尿病和高血压风险轻度升高相关,早产风险降低。
- SG中高血压风险升高仅见于高代谢风险药物(奥氮平、喹硫平、氯氮平)。
核心结论
- 与停药相比,妊娠期继续使用FG不增加母体风险,但NICU入住率更高。
- 继续使用SG与母体代谢风险增加及早产风险降低相关。
研究设计与样本
- 丹麦全国基于人群的队列研究,纳入2004-2022年活产单胎,孕前1年至孕30天前配药≥1次抗精神病药。
- 共7417例妊娠,FG暴露453例(6.1%),SG暴露2219例(29.9%),停药4745例。
- 继续使用定义为孕20周(妊娠并发症)或全孕期(出生结局)持续用药。
主要发现
- SG继续者妊娠糖尿病OR=1.19(95%CI 0.96-1.48),妊娠高血压OR=1.20(95%CI 0.97-1.48)。
- FG继续者妊娠糖尿病OR=0.92(95%CI 0.57-1.48),妊娠高血压OR=1.01(95%CI 0.60-1.71)。
- SG继续者早产OR=0.77(95%CI 0.64-0.93);FG继续者早产OR=1.13(95%CI 0.80-1.60)。
- FG继续者NICU入住OR=1.28(95%CI 1.01-1.62);SG继续者NICU入住OR=0.87(95%CI 0.73-1.03)。
- 高代谢风险SG与低代谢风险SG的妊娠糖尿病风险相似,妊娠高血压风险升高仅见于高代谢风险SG。
临床怎么用
- 孕期继续SG需监测妊娠糖尿病和高血压,尤其高代谢风险药物。
- FG继续者应关注新生儿NICU入住风险。
- SG继续可能与早产风险降低相关,但需结合个体情况权衡。
局限性
- 观察性设计不能排除残余混杂。
- 仅纳入活产单胎,可能遗漏其他妊娠结局。
- 药物暴露基于处方配药,未验证实际服用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antipsychotic use in pregnancy has increased, but evidence on potential maternal and neonatal complications remains limited. OBJECTIVE: To evaluate the associations between continued first-generation antipsychotic (FG) or second-generation antipsychotic (SG) use during pregnancy and the risks of pregnancy complications and adverse birth outcomes. STUDY DESIGN: We conducted a population-based cohort study including all liveborn singletons born to women in Denmark (2004-2022) who filled ≥1 antipsychotic prescription from one year to 30 days before conception. Women who continued FGs or SGs through 20 gestational weeks (for pregnancy complications) or throughout pregnancy (for birth outcomes) were classified as continuers. SGs were further categorized into high metabolic risk (olanzapine, quetiapine, clozapine) or low metabolic risk (risperidone, aripiprazole, ziprasidone). Outcomes included gestational diabetes, gestational hypertension, and adverse birth outcomes identified from medical records. Adjusted odds ratios (ORs) were estimated using generalized estimating equations, accounting for maternal characteristics and psychiatric history. RESULTS: Among 7,417 pregnancies, 453 (6.1%) were exposed to FGs, 2,219 (29.9%) to SGs, and 4,745 discontinued treatment. Compared with their respective discontinuers, continuing SGs was associated with higher odds of gestational diabetes (OR = 1.19, 95% CI 0.96-1.48) and gestational hypertension (OR = 1.20, 95% CI 0.97-1.48), whereas no increased risk was observed for FGs (OR = 0.92, 95% CI 0.57-1.48 and OR = 1.01, 95% CI 0.60-1.71, respectively). Risks were similar for high- and low-metabolic risk SGs for gestational diabetes, whereas the increased risk of gestational hypertension was confined to high-metabolic risk SGs. Preterm birth was less common among SG continuers (OR = 0.77, 95% CI 0.64-0.93), but not among FG continuers (OR = 1.13, 95% CI 0.80-1.60). Neonatal intensive care unit admission was more frequent among FG continuers (OR = 1.28, 95% CI 1.01-1.62), but not among SG continuers (OR = 0.87, 95% CI 0.73-1.03). CONCLUSIONS: Continuation of FGs during pregnancy was not associated with increased maternal risk but was associated with higher rates of neonatal intensive care admission, compared with discontinuation. Continuation of SGs was associated with increased maternal metabolic risk and a lower risk of preterm birth.
引用
- Blæhr EE, Semark BD, Petersen LV, et al. First- and second-generation antipsychotic use in pregnancy and risks of pregnancy and birth outcomes. Am J Obstet Gynecol MFM. 2026. PMID: 42982132. doi:10.1016/j.ajogmf.2026.102185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。